The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors through allosteric signaling.

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...

Adhesion GPCRs are a large class of surface proteins that recognize chemical and mechanical stimuli in the body. The rapidly expanding body of knowledge on the therapeutic targeting of these receptors ...

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is ...

Researchers at Leipzig University and Shandong University have summarised the therapeutic potential of these receptors in a high-profile study. At present, 17 of the 33 known human adhesion GPCRs are ...

Executives from Crinetics Pharmaceuticals (NASDAQ:CRNX) used an investor discussion at TD Cowen’s 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched ...

In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...

Cone snails deploy sophisticated venom cocktails to paralyse prey. Anthony King talks to the researchers harnessing these peptides to develop new pain medications ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...